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The effect of polyphenol-rich dark chocolate on fasting capillary whole
blood glucose, total cholesterol, blood pressure and glucocorticoids in
healthy overweight and obese subjects
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Numerous studies indicate that polyphenol-rich chocolate reduces fasting blood glucose, blood pressure (BP) and total cholesterol in healthy
individuals and hypertensives with or without glucose intolerance. The aim of the present study was to investigate the effect of two doses of
polyphenol-rich dark chocolate (DC) on fasting capillary whole blood glucose, total cholesterol and BP and to examine whether improvements
in these parameters are associated with changes in adrenocorticoid excretion in overweight and obese individuals. The study used a randomised,
single-blind, cross-over design where fourteen overweight and obese subjects were randomised to either take 20 g DC with 500 mg polyphenols
then 20 g DC with 1000 mg polyphenols or vice-versa. Participants followed each diet for 2 weeks separated by a 1-week washout period. It was
observed that the 500 mg polyphenol dose was equally effective in reducing fasting blood glucose levels, systolic BP (SBP) and diastolic BP
(DBP) as the 1000 mg polyphenol dose suggesting that a saturation effect might occur with increasing dose of polyphenols. There was also a
trend towards a reduction in urinary free cortisone levels with both groups although it did not reach statistical significance. No changes in anthro-
pometrical measurements were seen. We suggest that more research is required to investigate the mechanism(s) by which polyphenol-rich foods
influence health.
Dark chocolate: Glucose: Blood pressure: Cholesterol: Glucocorticoids: Obesity
Epidemiological studies link high polyphenol intake with
reduced risk of oxidative stress-related diseases like diabetes,
hypertension and CVD(1 – 3). In particular, consumption of
cocoa and dark chocolate (DC) has been shown to improve
endothelium function, insulin sensitivity, blood pressure
(BP) in healthy individuals, hypertensives with or without
glucose intolerance(4 – 6) and obese subjects(7). Cocoa and
DC are rich sources of polyphenols providing on average
more polyphenols per serving than red wine, green tea or
black tea(8). These polyphenols confer potent antioxidant
properties to cocoa and DC(8,9) in addition to the ability to
regulate NO(4 – 7).
Obesity is known to be associated with insulin resistance
and elevated BP(10). One of the underlying factors linked to
these cardiovascular risk factors is abnormal cortisol metab-
olism(11,12). Cortisol is a counterregulatory hormone that is
essential in the long-term maintenance of blood glucose(13)
and which could also unfavourably influence BP and lipid
profile(12 – 15). When present in excess, cortisol induces
overproduction of reactive oxygen species(16,17) leading to
reduced endothelial NO synthase expression(18). In obesity,
particularly abdominal obesity, postprandial hypercortisolism
and enhanced peripheral metabolism of cortisol, characterised
by increased urinary cortisone-to-cortisol ratio, are observed
which are linked to insulin resistance and increased fasting
insulin(11). Increased expression of subcutaneous adipose
tissue 11b-hydroxysteroid dehydrogenase type 1 has also
been reported, which is known to impair glucose-stimulated
insulin secretion(19). Since improved NO bioavailability is
the main mechanism by which DC polyphenols reduce
endothelium dysfunction, insulin resistance and hyperten-
sion(4 – 7), this preliminary study aimed to assess and compare
the effect of DC containing two different doses of polyphenols
on fasting capillary whole blood glucose levels, total choles-
terol, BP, urinary free cortisol and cortisone excretion in
healthy overweight and obese subjects. The other objective
was to observe whether improvements in fasting blood
glucose, total cholesterol and BP could be correlated
with changes in urinary free cortisol or cortisone excretion.
A secondary objective was to monitor Mg intake and excretion
since DC is known to contain large quantities of Mg,
which, in turn, could influence BP, insulin action and the
metabolic syndrome(20 – 22).
*Corresponding author: Emad Al-Dujaili, fax þ44 131 474 0001, email ealdujaili@qmu.ac.uk
Abbreviations: BP, blood pressure; DBP, diastolic BP; DC, dark chocolate; FG, fasting glucose; SBP, systolic BP.
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Methods
Study design
The study used a randomised, cross-over design where each
subject acted as their own control. Following a 1-week
run-in phase, eligible subjects were randomly assigned to
one of the two polyphenol doses: 500 mg polyphenols DC or
1000 mg polyphenols DC. Participants followed each interven-
tion for 2 weeks, after which they were crossed-over to the
next intervention separated by a 1-week washout period
(Fig. 1). The study included healthy non-smoker volunteers,
aged 19–50 years with BMI $25 kg/m2 (23), no history
of diabetes, hypertension or CVD. People taking dietary sup-
plements, BP or cholesterol-lowering drugs, or those with soya
and nut allergies were excluded. Smokers were excluded
to minimise confounding factors since nicotine consumption
is known to enhance hypothalamic–pituitary–adrenal axis
activity, hence resulting in elevated cortisol levels(24,25).
Participants gave written consent, completed a lifestyle ques-
tionnaire before being screened for fasting blood glucose, total
cholesterol, BP and BMI to determine their eligibility. The
study was conducted according to the guidelines laid down
in the Declaration of Helsinki, and all procedures were
approved by Queen Margaret University Ethics Committee.
Diet
Table 1 provides a summary of the nutrient composition of the
two Acticoa DC used in the present study, which were kindly
supplied by Barry Callebaut (Lebbeke, Belgium). The 500 mg
dose was previously shown to reduce fasting glucose (FG)
levels and BP by Grassi et al. (4,5) and Taubert et al. (26).
However, due to the great variation in epicatechin and cate-
chin levels between the chocolate used in the present study
and the one used by Grassi et al. (4,5), a higher DC dose of
1000 mg was also chosen. This 1000 mg dose was selected
to provide similar quantities of polyphenol to what is
consumed by the Kuna population of Panama, who are
known to consume large quantities of cocoa and to have
low incidence of hypertension(27). This dose will also provide
about 43·2 % of the epicatechin and catechin dose used by
Grassi et al. (4,5). Subjects were instructed to distribute DC
doses throughout the day to achieve a high steady-state
concentration. They were also instructed to maintain their
usual diet throughout the study but to refrain from polyphe-
nol-rich foods and beverages that supply $15 mg/kg epicate-
chin and $4 mg/l epicatechin(28 – 30). Subjects completed a 3-d
(two weekdays and one weekend) diet and physical activity(31)
diary during the run-in phase and at the end of each dietary
intervention. The Photographic Atlas of Food Portion Sizes
was used to assist subjects in describing their portion
sizes(32). Diet diaries were validated by interviewing the
subjects using a validated questionnaire(33). The diet diaries
were analysed and energy, fat, protein, carbohydrate and
magnesium intake were estimated using Windiet software
(Windiet Research, Univation Ltd, Robert Gordon University,
Aberdeen, UK). Compliance with the study’s protocol was
assessed by direct interviewing, returning of empty chocolate
foils and assessment of diet diaries.
Measurements
To measure fasting blood glucose and total cholesterol, 12-h
fasting capillary whole blood samples were obtained and
analysed using a calibrated Accutrend GC system (Roche
diagnostics, Mannheim, Germany). Participants were
instructed to consume the last DC dose 12 h before ana-
lyses(34), avoid heavy physical activity and alcohol intake
24 h before testing and consume the same diet the day
before each test(30). Waist circumference, hip circumference
and BMI were measured. Data on waist and hip circumference
were used to calculate waist-to-hip ratio, where waist-to-hip
ratio .1·0 in men and .0·85 in women indicate abdominal
obesity(35). Both waist circumference and BMI serve as
good indicators of the degree of insulin resistance in
overweight and obese individuals(35) while waist-to-hip ratio
serves as a predictor of hypertension(36) and hypothalamic-
pituitary–adrenal axis hyperactivity, characterised by high
baseline plasma cortisol and low 24-h urinary cortisol
excretion in obese women(11). An automated A&D Medical
UA-767 BP monitor (A&D Medical, San Jose, CA, USA)
was used to measure BP according to Grassi et al. (5). This
monitor was previously validated and was shown to achieve
grade A for both systolic and diastolic BP according to the
British Hypertension Society standard(37).
Urine samples were obtained for estimating 24-h urinary
Mg excretion. Urinary Na and K excretion were also
Twenty-one individuals screened for fasting
blood glucose, total cholesterol, BP,
BMI
Fourteen selected and
randomised
500 mg
polyphenols DC
1000 mg
polyphenols DC
Washout
Run-in
500 mg
polyphenols DC
1000 mg
polyphenols DC
Seven excluded:
Five did not meet
eligibility criteria
One had BP
< 100/60 mmHg
Three had BMI
< 25 kg/m2
One consumed soya
and green tea
regularly
Two refused to participate
Fig. 1. Diagram showing random allocation of subjects into the different
dietary interventions. BP, blood pressure; DC, dark chocolate.
Table 1. Nutritional composition of 20 g of 500 and 1000 mg polyphenol
dark chocolate (DC)
Component 500 mg DC 1000 mg DC
Polyphenols (mg) 500 1000
Epicatechin and catechin (mg) 18·99 37·98
Energy (kJ) 425·8 425·8
Fat (g) 7·34 7·34
Protein (g) 1·34 1·34
Carbohydrate (g) 7·44 7·44
Mg (mg) 33·42 33·42
Na (mg) 1·4 1·4
K (mg) 168·42 168·42
S. Almoosawi et al.2
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monitored since they serve as direct measures of Na and K
intake, which could act as confounding factors in relation to
BP. The 24-h urine collections were validated by measuring
creatinine excretion(38,39). Analyses of urine Na, K and Mg
concentrations were conducted using an automated platform
(Olympus, Essex, UK) at the Clinical Biochemistry Labora-
tory, Royal Infirmary of Edinburgh, Scotland, UK. Urinary
cortisol and cortisone levels were analysed in duplicates
using ELISA according to the method described by Al-Dujaili
& Bryant(40) and Al-Dujaili(41). The data were then used to
calculate urinary cortisol-to-cortisone ratio. This ratio serves
as a measure of renal 11b-hydroxysteroid dehydrogenase
type 2 activity(42). Monitoring the activity of this enzyme
helps detect changes in peripheral metabolism of cortisol(42).
All tests were carried out at baseline, before and after each
intervention.
Statistical methods
All data are expressed as means and standard deviations.
Mixed between–within subjects ANOVA or split-plot
ANOVA was performed for multiple comparison, where
time (baseline, week 1, week 2) was the within-group variable
and intervention group (500 mg, 1000 mg DC) was the
between-group variable and the continuous variable were
FG, SBP, DBP BMI, weight, waist circumference, hip circum-
ference and waist-to-hip circumference. A P-value #0·05 was
considered statistically significant. Within each intervention
group (500, 1000 mg DC), changes in fasting blood glucose
levels, SBP and DBP were analysed using repeated measures
ANOVA with Bonferroni post hoc tests. A separate split-plot
ANOVA was also performed to detect any carry-over effects
between the two interventions and to ensure changes in FG,
SBP and DBP following each treatment were not affected
by the sequence of DC administration (1000 mg followed by
500 mg v. 500 mg followed by 1000 mg). Two-tailed paired
sample t tests were used to assess changes between baseline
and post-intervention total cholesterol, urinary free cortisol
or cortisone, urinary cortisol-to-cortisone ratio and mineral
excretion. Similarly, differences in response to both DC
doses among the various ethnic groups were assessed using
one-way between-groups ANOVA with FG, SBP and DBP
as the dependent variables and ethnicity as the factor. An inde-
pendent sample t test was also used to compare the response to
DC polyphenols between the abdominally obese individual
and the peripherally obese individuals. The relationship
between fasting blood glucose levels, total cholesterol,
SBP, DBP, BMI, weight, waist circumference, hip circum-
ference, waist-to-hip circumference, urinary Mg, Na and
K levels, 24-h urinary free cortisol, cortisone and cortisol-to-
cortisone ratio were assessed using Pearson product-moment
correlation coefficient, r. The coefficient of determination
was estimated by obtaining r 2. All statistical analyses were
performed using SPSS for Windows, version 16.0.0 (SPSS
Inc., Chicago, IL, USA). The sample size was calculated
using G-power software version 3.0.8 (Heinrich Heine
University, Dusseldorf, Germany) to detect 0·3 mmol/l
reduction in FG with baseline SD ¼ 0·5 mmol/l and post-
DC SD ¼ 0·04 mmol/l, which is similar to the reduction
reported by Grassi et al. (6).
Results
The study included fourteen healthy volunteers (eight males
(five Caucasians, two Asians, one African) and six females
(five Caucasians and one Hispanic)), 21–50 years old, mean
age 26·4 (SD 11·5) years) with a BMI of 27·7 (SD 2·5) kg/m2.
Of these participants, thirteen were peripherally obese and one
was abdominally obese (African).
Mixed between–within subjects ANOVA revealed a signifi-
cant reduction in fasting capillary blood glucose concentrations
(P¼0·002), SBP (P,0·0001) and DBP (P,0·0001) following
DC consumption. These effects were independent of the
sequence of DC administration and no significant interaction
between time, intervention group and sequence of DC admin-
istration was observed (FG F(2,11) ¼ 1·057, P¼0·380; SBP
F(2,11) ¼ 0·431, P¼0·660; DBP F(2,11) ¼ 0·653, P¼0·539;
Figs. 2 and 3). No significant differences between the effect
of 1000 and 500 mg polyphenols DC on fasting capillary
blood glucose (P.0·05) and BP (P.0·05) were observed
indicating that both doses have a similar efficacy.
To explore the results further, a one-way repeated measures
ANOVA was conducted to compare fasting blood glucose
levels, SBP and DBP at baseline, week 1 and week 2 for
each of the two dietary interventions. A significant effect of
DC on fasting blood glucose levels (F(2,12) ¼ 4·305,
P¼0·039), SBP (F(2,12) ¼ 12·330, P¼0·001) and DBP
(F(2,12) ¼ 13·937, P¼0·001) was observed after consumption
of 1000 mg DC. Post hoc comparisons using Bonferroni test
indicated that mean fasting blood glucose levels and SBP at
week 2 were significantly decreased after chocolate ingestion
(FG 3·97 (SD 0·54) v. baseline 4·42 (SD 0·70) mmol/l; SBP
112·12 (SD 9·68) v. baseline 119·38 (SD 10·51) mmHg).
Mean DBP levels were significantly lower at week 1 (74·45
(SD 7·17) mmHg) and week 2 (74·57 (SD 7·39) mmHg)
compared to baseline (78·62 (SD 7·74) mmHg).
A significant effect of 500 mg DC on FG levels
(F(2,12) ¼ 5·026, P¼0·026), SBP (F(2,12) ¼ 11·971,
P¼0·001) and DBP (F(2,12) ¼ 7·709, P¼0·007) was also
observed. Post hoc comparisons indicated that the mean FG
levels at week 2 were significantly different from baseline
(3·92 (SD 0·86) v. 4·42 (SD 0·30) mmol/l). Mean SBP was
also reduced at the end of week 1 (114·24 (SD 9·53) mmHg)
3·0
3·5
4·0
4·5
5·0
5·5
6·0
0 1 2 4 5 0 1 2 4 5
Group 2 (500 mg–1000 mg)
Week
FG
 (
m
m
o
l/l
)
Group 1 (1000 mg–500 mg)
Fig. 2. Capillary fasting glucose (FG) levels at baseline (week 0), and at the
end of 1and 2 weeks of each of the polyphenols doses. Group 1 received
1000 mg polyphenols dark chocolate (weeks 1–2) followed by 500 mg poly-
phenols dark chocolate (weeks 4–5). Group 2 received 500 mg polyphenols
dark chocolate (weeks 1–2) followed by 1000 mg polyphenols dark chocolate
(weeks 4–5). Changes in FG were independent of the sequences of choco-
late administration (P.0·05). Values are means with their standard errors
represented by vertical bars.
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and week 2 (112·40 (SD 9·51) mmHg) as compared to baseline
(119·38 (SD 10·51) mmHg). Similar findings were observed
with DBP (Week 1 ¼ 74·62 (SD 4·27) and Week 2 ¼ 73·00
(SD 5·06) v. baseline 78·62 (SD 7·74) mmHg).
Total cholesterol did not change significantly after 1000 mg
(P¼0·191) or 500 mg polyphenols DC (P¼0·246). There was
a trend towards a reduction in 24-h urinary free cortisone
levels in both the 1000 and 500 mg DC groups, although
this reduction did not reach statistical significance even after
adjustment for weight. No changes in anthropometrical data
(Table 2), 24-h urinary free cortisol, cortisol-to-cortisone
ratio, 24-h urinary Mg, Na, K were observed (Table 3). Like-
wise, one-way ANOVA revealed no significant effect of ethni-
city on changes in FG, SBP, DBP in both DC groups, with the
exception of one female subject (Hispanic), who experienced
a greater reduction in SBP following both polyphenol doses
as compared to Caucasians (1000 mg, P¼0·009; 500 mg,
P,0·0001), Asians (1000 mg, P¼0·014; 500 mg P¼0·003)
and African (1000 mg, P¼0·0001; 500 mg, P,0·009). The
subject with abdominal obesity showed an increase in urinary
free cortisol following 1000 mg polyphenols (þ52·44 nmol/d)
compared to peripherally obese individuals, who demonstrated
a reduction (211·05 nmol/d; P¼0·037). This subject also had
a greater reduction in DBP following 500 mg DC compared to
other individuals (215·7 mmHg v. 23·10 mmHg; P¼0·017).
Pearson’s product-moment correlations revealed a signifi-
cant correlation between changes in 24-h urinary free cortisol,
cortisone and changes in 24-h Na excretion (Table 4). There
were no significant correlations between age and changes in
FG, SBP, DBP following both DC doses (P.0·05). Addition
of DC to the diet did not affect Mg intake or excretion
100
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 (
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Group 2 (500 mg–1000 mg)Group 1 (1000 mg–500 mg)
Group 2 (500 mg–1000 mg)Group 2 (1000 mg–500 mg)
Fig. 3. Systolic blood pressure (SBP) (a) and diastolic blood pressure (DBP)
(b) at baseline (week 0), and at the end of 1 and 2 weeks of each of the poly-
phenols doses. Group 1 received 1000 mg polyphenols dark chocolate (weeks
1–2) followed by 500 mg polyphenols dark chocolate (weeks 4–5). Group 2
received 500 mg polyphenols dark chocolate (weeks 1–2) followed by
1000 mg polyphenols dark chocolate (weeks 4–5). Changes in SBP and DBP
were independent of the sequences of chocolate administration (P.0·05).
Values are means with their standard errors represented by vertical bars.
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significantly. Moreover, no significant correlations were found
between changes in Mg intake or excretion and the reductions
in fasting blood glucose and BP seen following DC consump-
tion. Energy expenditure, energy, macronutrient and mineral
intake did not change significantly through the study period
(Fig. 4).
Discussion
The present study demonstrates that polyphenol-rich DC
reduces fasting blood glucose levels and BP in overweight and
obese individuals. These findings are consistent with previous
observations that polyphenol-rich DC intake improved insulin
resistance, insulin sensitivity, FG levels and BP in healthy
individuals(4), hypertensives(5), glucose-intolerant hyperten-
sives(6) and obese subjects(7). The results are also in agreement
with studies on diabetic obese mice, where reductions in blood
glucose and fructosamine levels were reported following
consumption of cacao liquor procyanidins(43).
Enhanced vascular function is thought to be the main mech-
anism by which DC polyphenols improve glucose and BP
homeostasis(4 – 7,23,34,44 – 47), although other mechanisms like
decreased and delayed carbohydrate digestion and absorption
might also be involved(48,49). The present study investigated
whether polyphenol-rich DC could alter cortisol metabolism
and whether improvements in glucose and BP seen in obese
individuals following DC consumption are linked to improved
cortisol metabolism. The hypothesis was based on that cortisol
plays an important role in glucose and BP homeostasis,
probably through a mechanism involving increased reactive
oxygen species production and decreased NO bioavailability,
and that in obesity several alteration in cortisol metabolism
are observed, which are, in turn, linked to increased insulin
resistance and hypertension. The study demonstrates that
both 500 and 1000 mg polyphenol DC decrease 24-h urinary
free cortisol and cortisone levels. However, these reductions
were not significant and are not associated with reductions
in fasting blood glucose or BP. Such findings differ from
previous findings, wherein polyphenols increased(50 – 53) or
decreased(54,55) cortisol levels(56). The lack of significance
could be related to a number of factors. For instance, the
sample size might have not been sufficiently large to detect
a significant change. In this case, using several parameters
of cortisol metabolism including its measurement in urine,
saliva and blood might have helped detect any such effect.
Additionally, the study population consisted mainly ofT
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Table 4. Pearson product-moment correlations between changes in
urinary glucocorticoid levels and changes in selected parameters
Correlation pair n r P
DUrinary free cortisol (nmol/kg per 24 h)
DUrinary free cortisone excretion
(nmol/kg per 24 h)
27 0·599 0·001
D 24 h urinary Na (mmol/g creatinine) 26 0·489 0·011
DPhysical activity (kJ) 26 20·384 0·053
DUrinary free cortisone (nmol/kg per 24 h)
DCortisol-to-cortisone ratio 27 20·662 0·000
DCortisone-to-cortisol ratio 27 0·628 0·000
D 24 h urinary Na (mmol/g creatinine) 26 0·478 0·014
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subjects with peripheral obesity rather than those with
abdominal obesity, who exhibit more prominent abnormalities
in cortisol metabolism as indicated by the association between
high waist circumference or waist-to-hip ratio and high urin-
ary cortisol or cortisone-to-cortisol ratio(11,57). In addition,
differences in Na intake were not controlled for and could
have acted as confounding factors(58). This could be observed
in the association between changes in urinary free cortisol or
cortisone and changes in Na excretion, and the association
between changes in Na intake and changes in cortisol-to-cor-
tisone ratio. Dietary factors have been reported to influence
cortisol metabolism. High-fat low-carbohydrate diets stimulate
cortisol regeneration by 11b-hydroxysteroid dehydrogenase
type 1, while reducing cortisol inactivation in liver(59). Na
loading, on the other hand, decreases plasma cortisol levels
by enhancing cortisol elimination(60) possibly via a mechan-
ism involving increased hepatic blood flow(61). The latter
may explain the association between increased urinary free
cortisol excretion and urinary Na levels. However, subjects
did not report significant changes in Na intake during the
study, which overall suggest that DC polyphenols influence
glucose and BP homeostasis mainly via the NO pathway.
The present study demonstrates that DC with 500 mg poly-
phenols is as effective in reducing fasting blood glucose levels
in overweight and obese individuals as 1000 mg polyphenol
DC with a similar macronutrient composition. Furthermore,
the results indicate that DC polyphenols reduce blood glucose
levels after 2 weeks of commencing a polyphenol-rich DC
diet. These findings are important since in relation to glucose
metabolism, inconsistencies still exist regarding the treatment
duration and dose required to achieve a glucose-lowering
effect. For example in their pilot study, Stote et al. (62)
failed to show any significant improvement in glucose
levels, insulin resistance and insulin sensitivity following 5 d
of twice daily consumption of procyanidin-rich cocoa bever-
age containing 22–900 mg procyanidins by insulin-resistant
men and women. Similarly, Taubert et al. (34) failed to demon-
strate any improvement in glucose or insulin levels following
18 weeks of daily ingestion of 6·3 g DC containing 30 mg
polyphenols. Conversely, Davison et al. (7) showed reduced
insulin resistance following consumption of a cocoa
beverage containing 902 mg flavanols twice daily for 12
weeks in overweight and obese subjects. Together, these find-
ings suggest that a longer duration and a higher dose of
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Fig. 4. Energy (I), macronutrient (II) and mineral intake (III) at baseline and at the end of each intervention: (a) 20 g dark chocolate with 1000 mg polyphenols and
(b) 20 g dark chocolate with 500 mg polyphenols. Values are means with their standard errors represented by vertical bars. ( ), Energy expenditure; ( ) energy
intake; ( ) fat intake; ( ) protein intake; ( ) carbohydrate intake; ( ) Mg intake; ( ) Na intake; ( ) K intake.
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polyphenols could be required to achieve a significant
reduction in glucose levels. The present study reinforces this
hypothesis while demonstrating that increasing polyphenol
dose does not necessarily results in further reductions in
glucose and BP levels since a saturation effect may occur
with increasing DC polyphenol content(63). It also highlights
the need to identify the minimum polyphenol dose at which
maximal health benefits could be achieved, since a reduction
in the polyphenol content of chocolate implies reduced bitter-
ness(64,65), which could render the chocolate more palatable
and acceptable to the general population. In relation to BP,
20 g DC with 500 mg polyphenols reduced SBP and DBP
to a similar extent as 20 g DC with 1000 mg polyphenol.
Moreover, the reduction in BP observed following the 20 g
DC (500 mg polyphenols) was comparable to the reduction
reported in a previous study on normotensive subjects (7 and
3 mmHg reduction in SBP and DBP, respectively)(4). This
might suggest that reducing the portion of DC while maintain-
ing a similar total phenol content results in equivalent
reductions in BP. This could provide several advantages since
reducing the portion of DC would permit delivery of high quan-
tity of polyphenols in a less energy-dense form, which is essen-
tial if DC is to be included as part of a healthy balanced diet.
In contrast to Fraga et al. (66) and Grassi et al. (5), we did not
observe any significant changes in total cholesterol. Such
results are to be expected since our subjects had normal
baseline total blood cholesterol levels as compared to Grassi
et al. (5) (baseline total cholesterol ¼ 5·4 (SD 0·6) mmol/l).
Moreover, Grassi et al. (5) suggested that both the catechin
and the fat component of DC account for its beneficial
effect on total cholesterol. Similar assumptions were made
in relation to stearic acid in DC(67). Since in the present
study a lower DC portion was used, the lack of significant
change in total blood cholesterol could be related to the
lower levels of linoleic, oleic and stearic acids present in
this DC. There was also a lack of correlation between the
reported energy intake and physical activity, which is similar
to the findings of Davison et al. (7), who argued that obese
individuals might underreport energy intake and overreport
physical activity.
In conclusion, the present study confirms previous reports
of improved FG levels and BP following DC consumption.
It also demonstrates that these effects do not appear to be
mediated through changes in cortisol metabolism. Further
studies are needed to identify the optimal dose of polyphenols
required to improve glucose metabolism and to examine
additional parameters that could be influenced by polyphenols.
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